Latest & greatest articles for naproxen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on naproxen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on naproxen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for naproxen

21. Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib 18474729 2008 07 15 2008 08 04 2017 02 20 1538-3687 65 7 2008 Jul Archives of neurology Arch. Neurol. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. 896-905 10.1001/archneur.2008.65.7.nct70006 Observational (...) studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. Randomized, double-masked chemoprevention trial. Six US memory clinics. Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

22. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. 18514729 2008 06 02 2008 06 23 2015 06 16 1474-547X 371 9627 2008 May 31 Lancet (London, England) Lancet Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. 1854-60 10.1016/S0140-6736(08)60799-0 Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal (...) , and cardiovascular adverse effects. Systemic corticosteroids might be a beneficial alternative. We investigated equivalence of naproxen and prednisolone in primary care. We did a randomised clinical trial to test equivalence of prednisolone and naproxen for the treatment of monoarticular gout. Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible. 120 patients were randomly assigned with computer-generated randomisation to receive either prednisolone (35 mg once a day

Lancet2008

23. Treximet (sumatriptan and naproxen sodium)

Treximet (sumatriptan and naproxen sodium) Drug Approval Package: Treximet (sumatriptan and naproxen sodium) NDA #021926 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Treximet (sumatriptan and naproxen sodium) Tablets Company: Pozen Inc. Application No.: 021926 Approval Date: 04/15/2008 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s

FDA - Drug Approval Package2008

24. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.

Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. 17405970 2007 04 04 2007 04 06 2016 10 17 1538-3598 297 13 2007 Apr 04 JAMA JAMA Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. 1443-54 Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy. To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate (...) and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine. Two replicate, randomized, double-blind, single-attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack. Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen

JAMA2007

25. Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults

Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults Article Text Treatment Review: a single dose of oral naproxen or naproxen sodium reduced acute postoperative pain in adults Free Tracey Bucknall , PhD , RN

Evidence-Based Nursing (Requires free registration)2006

26. Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs

Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs Article Text Therapeutics Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other

Evidence-Based Medicine (Requires free registration)2006

27. Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease

Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Article Text Therapeutics Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease Free Robin Jacoby , DM FRCP FRCPsych Statistics from Altmetric.com No Altmetric data available for this article. ( 2003 ) JAMA 289

Evidence-Based Mental Health2004

28. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. 15325831 2004 08 24 2004 09 02 2016 11 24 1474-547X 364 9435 2004 Aug 21-27 Lancet (London, England) Lancet Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled (...) , naproxen and ibuprofen. 18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) for 52 weeks, in two substudies of identical design (lumiracoxib vs ibuprofen or naproxen). Randomisation was stratified for low-dose aspirin use and age. The primary endpoint was the difference in time-to-event distribution of upper gastrointestinal ulcer complications (bleeding

Lancet2004

29. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. 15325832 2004 08 24 2004 09 02 2016 11 24 1474-547X 364 9435 2004 Aug 21-27 Lancet (London, England) Lancet Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. 675-84 (...) The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. 18325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg

Lancet2004

30. Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis

Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis Gastrointestinal Tolerability and... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 139 , Issue: 7 , Pages: 539-546 ISSN: 00034819 Available from or Find this paper at: Abstract Background: Gastrointestinal (GI) toxicity mediated by dual cyclooxygenase (COX)-1 (...) and COX-2 inhibition of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious alterations of mucosal integrity or, more commonly, intolerable GI symptoms that may necessitate discontinuation of therapy. Unlike NSAIDs, rofecoxib targets only the COX-2 isoform. Objective: To assess the tolerability of rofecoxib compared with naproxen for treatment of osteoarthritis. Design: Randomized, controlled trial. Setting: 600 office and clinical research sites. Patients: 5557 patients (mean age, 63

Annals of Internal Medicine2003

31. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. 12783912 2003 06 04 2003 06 12 2016 12 08 0098-7484 289 21 2003 Jun 04 JAMA JAMA Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. 2819-26 Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests (...) that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease. To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD. Multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with 1-year exposure to study medications. Forty ambulatory treatment centers affiliated with the Alzheimer's Disease Cooperative Study consortium

JAMA2003

32. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 11274623 2001 03 16 2001 04 05 2014 11 20 0028-4793 344 13 2001 Mar 29 The New England journal of medicine N. Engl. J. Med. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 967-73 Many patients who have had upper gastrointestinal bleeding continue to take (...) recurrent bleeding. We recruited patients who presented with upper gastrointestinal bleeding that was confirmed by endoscopy. Their ulcers were healed by daily treatment with 20 mg of omeprazole for eight weeks or longer. Then, those who had been taking aspirin were given 80 mg of aspirin daily, and those who had been taking other NSAIDs were given 500 mg of naproxen twice daily for six months. The patients in each group were then randomly assigned separately to receive 20 mg of omeprazole daily for six

NEJM2001

33. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. 11087881 2000 11 08 2000 11 30 2017 03 17 0028-4793 343 21 2000 11 23 The New England journal of medicine N. Engl. J. Med. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. 1520-8, 2 p following 1528 Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who (...) are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis. We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis

NEJM2000

34. Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care.

Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. 10514160 1999 11 19 1999 11 19 2017 02 19 0959-8138 319 7215 1999 Oct 09 BMJ (Clinical research ed.) BMJ Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. 964-8 To compare the clinical effectiveness of local corticosteroid injection, standard non (...) -steroidal anti-inflammatory drugs, and simple analgesics for the early treatment of lateral epicondylitis in primary care. Multicentre pragmatic randomised controlled trial. 23 general practices in North Staffordshire and South Cheshire. 164 patients aged 18-70 years presenting with a new episode of lateral epicondylitis. Local injection of 20 mg methylprednisolone plus lignocaine, naproxen 500 mg twice daily for two weeks, or placebo tablets. All participants received a standard advice sheet and co

BMJ1999 Full Text: Link to full Text with Trip Pro